Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Note 9 - Other Expenses - Components of Research and Development Expenses (Details)

v3.10.0.1
Note 9 - Other Expenses - Components of Research and Development Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement Line Items [Line Items]        
Program costs, excluding salaries $ 2,773 $ 1,017 $ 7,249 $ 2,956
Salaries 502 321 1,448 1,064
License fee, CrystalGenomics (a),(b) [1],[2] 5,000
Stock-based compensation 307 43 826 168
Depreciation and amortization 9 9 26 25
$ 3,591 $ 1,390 $ 14,549 $ 4,213
[1] On June 13, 2018, the Company paid $3.0 million in cash to CrystalGenomics to gain an exclusive license to develop and commercialize CG-806 in China. Future milestone payments are described in note 10.
[2] On May 7, 2018, under the license agreement with CrystalGenomics the Company, the Company paid the option fee of $2.0 million in cash to CrystalGenomics in order to exercise early the option and gain an exclusive license to develop and commercialize CG-806 in all territories outside of Korea and China. Future milestone payments are described in note 10.